ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,615.35
      0.55%
      US Tech 100
      19,804.00
      0.64%
      Dow Jones
      40,000.90
      0.62%
      Brent Oil
      84.57
      0.00%
      Bitcoin
      60,146.88
      1.54%
      Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. Europe
      5. EU
      6. Galapagos (GLPG)

      7. Galapagos (GLPG) News

      GLPG

      Galapagos (GLPG)

      Galapagos
      		Date:
      Sort by:
       Showing the most relevant articles for your search:EU:GLPG
      DateTimeSourceHeadlineSymbolCompany
      05/15/20154:56AMPR NewswireBryan, Garnier & Co annonce l'introduction en bourse reussie pour 275 millions USD de Galapagos NV, la plus importante introd...EU:GLPGGalapagos
      05/14/20156:00AMGlobeNewswire Inc.Galapagos (Nasdaq: GLPG) to Ring The Nasdaq Stock Market Opening BellEU:GLPGGalapagos
      05/13/201511:22PMGlobeNewswire Inc.Galapagos raises $275 million gross proceeds with NASDAQ IPOEU:GLPGGalapagos
      05/06/20151:37AMGlobeNewswire Inc.Galapagos listed 10 years on Euronext Amsterdam and BrusselsEU:GLPGGalapagos
      05/06/20151:35AMGlobeNewswire Inc.Galapagos announces launch of proposed global offeringEU:GLPGGalapagos
      05/01/201512:05PMGlobeNewswire Inc.BNP Paribas notify of 4.8% shareholding in GalapagosEU:GLPGGalapagos
      05/01/201512:04PMGlobeNewswire Inc.Galapagos creates new warrant planEU:GLPGGalapagos
      04/27/20154:11PMGlobeNewswire Inc.Filgotinib as monotherapy also hits primary endpoint in DARWIN 2 trialEU:GLPGGalapagos
      04/15/20155:04PMGlobeNewswire Inc.Galapagos files registration statement in the United States for a proposed global offeringEU:GLPGGalapagos
      04/14/20154:09PMGlobeNewswire Inc.Galapagos' JAK1 inhibitor filgotinib (GLPG0634) meets primary and other key efficacy endpoints after 12 weeks of treatment in...EU:GLPGGalapagos
      03/27/20152:40PMGlobeNewswire Inc.Publication of Annual Report 2014 and invitation to the Annual Shareholders' Meeting to be held on 28 April 2015EU:GLPGGalapagos
      03/27/20152:34AMGlobeNewswire Inc.Galapagos raises EU5.8 million through warrant exercises, Board and Executive Committee members investEU:GLPGGalapagos
      03/17/20152:37AMGlobeNewswire Inc.Galapagos regains rights to GLPG1690, announces end of alliance with JanssenEU:GLPGGalapagos
      03/06/20151:48AMGlobeNewswire Inc.Galapagos to be included in Amsterdam Midcap IndexEU:GLPGGalapagos
      03/06/20151:36AMGlobeNewswire Inc.Galapagos reports 2014 financial resultsEU:GLPGGalapagos
      02/23/20151:36AMGlobeNewswire Inc.Galapagos reports that the last patient in DARWIN 1 has completed 12 weeks of treatmentEU:GLPGGalapagos
      02/16/20151:33AMGlobeNewswire Inc.Galapagos reports positive Phase 1 results for GLPG1690EU:GLPGGalapagos
      02/11/20151:33AMGlobeNewswire Inc.Galapagos receives EU1.6 million IWT grant for hepatitis B programEU:GLPGGalapagos
      02/09/20151:37AMGlobeNewswire Inc.BNP Paribas notify of 5.08% shareholding in GalapagosEU:GLPGGalapagos
      01/22/20151:36AMGlobeNewswire Inc.Galapagos receives EU2.5 million IWT grant for antibiotic researchEU:GLPGGalapagos
      01/21/201512:59PMGlobeNewswire Inc.Delta Lloyd notify of 4.96% shareholding in GalapagosEU:GLPGGalapagos
      01/09/20151:34AMGlobeNewswire Inc.Vicki Sato resigns from Galapagos BoardEU:GLPGGalapagos
      01/08/20151:38AMGlobeNewswire Inc.Galapagos starts Phase 2 trial with GLPG1205 in ulcerative colitis patientsEU:GLPGGalapagos
      12/19/20141:44AMGlobeNewswire Inc.Galapagos initiates first Phase 1 study in cystic fibrosis and will receive milestone payment from AbbVieEU:GLPGGalapagos
      12/16/20141:39AMGlobeNewswire Inc.Galapagos regains full rights to GPR84 inhibitor GLPG1205EU:GLPGGalapagos
      12/12/20141:38AMGlobeNewswire Inc.Galapagos selects second component of its investigational cystic fibrosis combination treatmentEU:GLPGGalapagos
      07/25/201412:03PMGlobeNewswire Inc.Galapagos creates new warrant planEU:GLPGGalapagos
      07/23/20141:41AMGlobeNewswire Inc.MorphoSys and Galapagos Advance Joint Antibody Program in Inflammatory Diseases into Preclinical DevelopmentEU:GLPGGalapagos
      07/04/201412:07PMGlobeNewswire Inc.Galapagos raises EU1.9 million through warrant exercisesEU:GLPGGalapagos
      07/01/20141:37AMGlobeNewswire Inc.Galapagos initiates Phase 1 study with GLPG1690, triggering EU6.6 M milestone in the alliance with Janssen Pharmaceutica NVEU:GLPGGalapagos
       Showing the most relevant articles for your search:EU:GLPG